BlackRock takes 5.1% position in ARS Pharmaceuticals (NASDAQ: SPRY)

Rhea-AI Filing Summary

BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 5,013,000 shares of ARS Pharmaceuticals, Inc. common stock, representing 5.1% of the class as of 12/31/2025. BlackRock reports sole voting power over 4,929,603 shares and sole dispositive power over 5,013,000 shares, with no shared voting or dispositive power.

The filing explains that these holdings are attributed to specific BlackRock business units and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares. BlackRock certifies that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of ARS Pharmaceuticals.

Insights

Institutional ownership analyst

BlackRock discloses a 5.1% passive stake in ARS Pharmaceuticals.

BlackRock, Inc. reports beneficial ownership of 5,013,000 ARS Pharmaceuticals common shares, equal to 5.1% of the class as of 12/31/2025. The firm has sole voting power over 4,929,603 shares and sole dispositive power over the full 5,013,000 shares, indicating centralized decision-making authority within the reporting business units.

The position is described as being held in the ordinary course of business and not with the purpose or effect of changing or influencing control. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single client exceeds five percent of the outstanding shares. As a Schedule 13G with a control-purpose disclaimer, this functions as a passive institutional ownership disclosure rather than a strategic control move.

FAQ

What stake does BlackRock report in ARS Pharmaceuticals (SPRY)?

BlackRock, Inc. reports beneficial ownership of 5,013,000 shares of ARS Pharmaceuticals, Inc. common stock, representing 5.1% of the outstanding class as of 12/31/2025.

Is BlackRock’s ARS Pharmaceuticals (SPRY) position reported as passive or for control purposes?

BlackRock certifies that the ARS Pharmaceuticals securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

How much voting power does BlackRock have over its ARS Pharmaceuticals shares?

BlackRock reports sole voting power over 4,929,603 ARS Pharmaceuticals common shares and no shared voting power.

What dispositive power does BlackRock hold over ARS Pharmaceuticals (SPRY) stock?

BlackRock has sole dispositive power over 5,013,000 ARS Pharmaceuticals common shares and reports no shared dispositive power.

Who ultimately benefits from BlackRock’s ARS Pharmaceuticals holdings?

The filing states that various persons have rights to receive dividends or sale proceeds from ARS Pharmaceuticals shares held by BlackRock’s business units, but no single person has an interest exceeding five percent of the total outstanding common shares.

What is the event date for BlackRock’s ARS Pharmaceuticals Schedule 13G?

The date of the event requiring the Schedule 13G filing for ARS Pharmaceuticals is listed as 12/31/2025.

Who signed the BlackRock Schedule 13G for ARS Pharmaceuticals (SPRY)?

The Schedule 13G was signed by Spencer Fleming, identified as a Managing Director of BlackRock, Inc., dated 01/21/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 12:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ARS Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

82835W108

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 82835W108

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,929,603.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,013,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,013,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ARS Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 82835W108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5013000
(b)	Percent of class: 5.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4929603
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5013000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ARS Pharmaceuticals, Inc.. No one person's interest in the common stock of ARS Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	01/21/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7